Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2016

01-12-2016 | Original Article

The evaluation of miRNAs on thyroid FNAC: the promising role of miR-375 in follicular neoplasms

Authors: Esther Diana Rossi, Tommaso Bizzarro, Maurizio Martini, Sara Capodimonti, Diletta Sarti, Tonia Cenci, Mirna Bilotta, Guido Fadda, Luigi Maria Larocca

Published in: Endocrine | Issue 3/2016

Login to get access

Abstract

Fine needle aspiration cytology (FNAC) plays an essential role in the evaluation of thyroid nodules especially for the category of follicular neoplasms (FN) representing 25 % of all thyroid cases including different neoplastic entities. Hence, one of the most promising areas is the application of molecular tests to FNAC. Among them, microRNAs (miRNA),identified as negative (post-transcriptional) gene expression regulators involved in tumor development, are likely to discriminate among FNs. Limited data explored the use of miRNAs on FNAC as well as their role in the malignant risk stratification. We aimed to define whether liquid-based cytology (LBC) is a valid method for miRNA evaluation. From June 2014 to March 2015, we enrolled 27FNs with histological follow-up. In the same reference period, 13 benign nodules (BN) and 20 positive for malignancy (PM) were selected as controls. Histologically, FNs resulted in 14 malignancies (3 papillary thyroid carcinoma-PTC and 11 follicular variant of PTC-FVPC) and 13 follicular adenomas (FA). The 20 PMs included two FVPC, 16 PTC and two medullary thyroid carcinoma (MTC). Five miRNAs (10b, 92a, 221/222 cluster, and 375) were studied on LBC and quantified by real-time PCR. Only miR-375 was over-expressed in the FNs diagnosed as carcinomas and in the PMs. A cut-off of 12 miR-375/U6 relative ratio recognized all BNs and 95 % PMs. Specifically, in each category, FVPCs and PTCs did not show any difference while MTCs had the highest value. miR-375 shows 97.1 % sensitivity, 100 % specificity, 96.3 % negative predictive value (NPV), 100 % positive predictive value (PPV), and 98.3 % diagnostic accuracy. LBC is suitable for miRNAs evaluation. miR-375 resulted over-expressed in all malignant FNs and 95 % PMs. It may represent a valid aid in ruling out BNs and supporting PTCs and/or FVPCs.
Literature
1.
J.A. Sosa, J.W. Hanna, K.A. Robinson et al., Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States. Surgery 154, 1420–1426 (2013)CrossRefPubMed
2.
C.M. Kiernan, J.T. Broome, C.C. Solozano, The Bethesda system for reporting thyroid cytopathology: a single-center experience over 5 years. Ann. Surg. Oncol. 21, 3522–3527 (2014)CrossRefPubMedPubMedCentral
3.
4.
H.H. Wang, Reporting thyroid fine-needle aspiration: literature review and a proposal. Diagn. Cytopathol. 34, 67–76 (2000)CrossRef
5.
D.N. Poller, A.K. Ibrahim, M.H. Cummings et al., Fine-needle aspiration of the thyroid. Importance of an indeterminate diagnostic category. Cancer Cytopathol. 90, 239–244 (2000)CrossRef
6.
G. Fadda, E.D. Rossi, M. Raffaelli et al., Follicular thyroid neoplasms can be classified as low and high risk according to HBME-1 and Galectin 3 expression on liquid based fine needle cytology. Eur. J. Endocrinol. 165, 447–453 (2011)CrossRefPubMed
7.
F. Pagni, M. Prada, P. Goffredo et al., ‘Indeterminate for malignancy’ (TIR3/Thy3 in the Italian and British systems for classification) thyroid fine needle aspiration (FNA) cytology reporting: morphological criteria and clinical impact. Cytopathol 25, 170–176 (2014)CrossRef
8.
J. Diggans, S.Y. Kim, Z. Hu et al., Machine learning from concept to clinic: reliable detection of BRAFV600E DNA mutations in thyroid nodules using high-dimensional RNA expression data. Pac. Symp. Biocomput. 20, 371–382 (2015)
9.
J.F. Krane, P.A. Vanderlaan, W.C. Faquin et al., The atypia of undetermined significance/follicular lesion of undetermined significance:malignant ratio. Cancer Cytopathol. 120, 111–116 (2012)CrossRefPubMed
10.
11.
H. Chen, I. Izevbaye, F. Chen et al., Recent advances in follicular variant of papillary thyroid carcinoma. N. Am. J. Med. Sci. 5, 212–216 (2012)CrossRef
12.
Walts AE, Mirocha JM, Bose S. Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status. J. Cancer Res. Clin. Oncol. 141, 1749–1756 (2015). doi:10.​1007/​s00432-015-1939-9 CrossRefPubMed
13.
E.S. Cibas, S.Z. Ali, The Bethesda system for reporting thyroid cytopathology. Thyroid 19, 1159–1165 (2009)CrossRefPubMed
14.
British Thyroid Association, Royal College of Physicians Guidelines for the management of thyroid cancer, 3rd edn. (RCP, London, 2014)
15.
F. Nardi, F. Basolo, A. Crescenzi et al., Italian consensus for the classification and reporting of thyroid cytology. J. Endocrinol. Invest. 37, 593–599 (2014)CrossRefPubMed
16.
B.C.G. Freitas, J.M. Cerutti, Genetic markers differentiating follicular thyroid carcinoma from benign lesions. Mol. Cell. Endocrinol. 321, 77–85 (2010)CrossRefPubMed
17.
H.G. Correia-Rodrigues, A.A. Nogueira De Pontes, L.F.F. Adan, Use of molecular markers in samples obtained from preoperative aspiration of thyroid. Endocr. J. 59, 417–424 (2012)CrossRef
18.
M.N. Nikiforova, Y. Nikiforov, Molecular diagnostics and predictors in thyroid cancer. Thyroid 19, 1351–1361 (2009)CrossRefPubMed
19.
G. Fadda, E.D. Rossi, Liquid based cytology in fine needle aspiration biopsies of the thyroid gland. Acta Cytol. 55, 389–400 (2011)CrossRefPubMed
20.
D. Dabbs, C.S. Abendroth, R.T. Grenko et al., Immunocytochemistry on the Thin-prep processor. Diagn. Cytopathol. 17, 388–392 (1997)CrossRefPubMed
21.
A. Longatto-Filho, A.E. Goncalves, O. Martinho et al., Liquid based cytology in DNA-based molecular research. Anal. Quant. Cytol. Histol. 31, 395–400 (2009)
22.
E.D. Rossi, M. Martini, S. Capodimonti et al., Diagnostic and prognostic value of immunocytochemistry and BRAF mutation analysis on liquid based biopsies of thyroid neoplasms suspicious for carcinoma. Eur. J. Endocrinol. 168, 853–859 (2013)CrossRefPubMed
23.
Y.E. Nikiforov, D.L. Steward, T.M. Robinson-Smith et al., Molecular testing for mutations in improving the fine needle aspiration diagnosis of thyroid nodules. J. Clin. Endocrinol. Metab. 94, 2092–2098 (2009)CrossRefPubMed
24.
H. Mazeh, I. Mizrahi, D. Halle et al., Development of a microRNA-based molecular assay for the detection of papillary thyroid carcinoma in aspiration biopsy samples. Thyroid 21, 111–118 (2011)CrossRefPubMed
25.
R. Shen, S. Liyanarachchi, W. Li et al., MicroRNA signature in thyroid fine needle aspiration cytology applied to “atipia of undetermined significance” cases. Thyroid 22, 9–16 (2012)CrossRefPubMedPubMedCentral
26.
M.N. Nikiforova, S.I. Chiosea, Y.E. Nikiforov, MicroRNA expression profiles in thyroid microRNAs in thryoid fine needle aspiration biopsy samples. Thyroid 22, 285–291 (2012)CrossRef
27.
M.N. Nikiforova, G.C. Tseng, D. Steward et al., MicroRNA expression profiling of thyroid tumors: biological significance and diagnistic utility. J. Clin. Endocrinol. Metab. 93, 1600–1608 (2008)CrossRefPubMedPubMedCentral
28.
H. Mazeh, Y. Levy, I. Mizrahi et al., Differentiating benign from malignant thyroid nodules using micro ribonucleic acid amplification in residual cells obtained by fine needle aspiration biopsy. J. Surg. Res. 180, 216–221 (2013)CrossRefPubMed
29.
X.M. Keutgen, F. Filicori, M.J. Crowley et al., A panel of four miRNAs accurately differentiates malignant from benign indeterminate thyroid lesions on fine needle aspiration. Clin. Cancer Res. 18, 2032–2038 (2012)CrossRefPubMed
30.
P. Pallante, R. Visone, M. Ferracin et al., MircoRNA deregulation in human thyroid papillary carcinomas. Endocr. Relat. Cancer 13, 497–508 (2006)CrossRefPubMed
31.
F. Weber, R.E. Teresi, C.E. Broelsch et al., A limited set of human microRNA is deregulated in follicular thyroid carcinoma. J. Clin. Endocrinol. Metab. 91, 3584–3591 (2006)CrossRefPubMed
32.
M.T. Tetzlaff, A. Liu, X. Xu, S.R. Master et al., Differential Expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr. Pathol. 18, 163–173 (2007)CrossRefPubMed
33.
Y.T. Chen, N. Kitabayashi, X.K. Zhou et al., MicroRNA analysis as a potential diagnostic tool for papillary thyroid carcinoma. Mod. Pathol. 21, 1139–1146 (2008)CrossRefPubMed
34.
S.Y. Sheu, F. Grabellus, S. Schwertheim et al., Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumors. Br. J. Cancer 102, 376–382 (2010)CrossRefPubMed
35.
Y. Peng, C. Li, D.C. Luo et al., Expression profile and clinical significance of microRNAs in papillary thyroid carcinoma. Molecules 19, 11586–11599 (2014)CrossRefPubMed
36.
C.K. Chou, R.F. Chen, F.F. Chou et al., miR-146 is highly expressed in adult papillary thyroid carcinoma with high risk features including extrathyroidal invasion and the BRAF (V600E) mutation. Thyroid 20, 489–494 (2010)CrossRefPubMed
37.
L. Yip, L. Kelly, Y. Shuai et al., MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann. Surg. Oncol. 18, 2035–2041 (2011)CrossRefPubMed
38.
J. Hudson, E. Duncavage, A. Tamburrino et al., Over expression of miR-10a and miR-375 and down regulation of YAP1 in medullary thyroid carcinoma. Exp. Mol. Pathol. 95, 62–67 (2013)CrossRefPubMedPubMedCentral
39.
J.W. Yan, J.S. Lin, X.X. He, The emerging role of miR-375 in cancer. Int. J. Cancer 135, 1011–1018 (2013)CrossRefPubMed
40.
T. Jikuzono, M. Kawamoto, H. Yoshitake et al., The miR-221/222 custer, miR-10B and miR-92a are highly upregulated in metastatic minimally invasive follicular thyroid carcinoma. Int. J. Oncol. 42, 1858–1868 (2013)PubMedPubMedCentral
41.
P. Agretti, E. Ferrarini, T. Rago et al., MicroRNA expression profile help to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine needle aspiration. Eur. J. Endocrinol. 167, 393–400 (2012)CrossRefPubMed
42.
Y. Zhang, Q. Zhong, X. Chen et al., Diagnostic value of microRNAs in discriminating malignant thyroid nodules from benign ones on fine needle aspiration samples. Tumor Biol. 35, 9343–9353 (2014)CrossRef
43.
M. Dettmer, A. Perren, H. Moch et al., Comprehensive microRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma. Thyroid 23, 1383–1389 (2013)CrossRefPubMedPubMedCentral
44.
M. Dettmer, A. Vogetseder, M.B. Durso et al., MicroRNA expression array identifies novel diagnostic markers for conventional and oncocytic follicular thyroid carcinomas. J. Clin. Endocrinol. Metab. 98, E1–E7 (2013)CrossRefPubMed
45.
American Joint Commission on Cancer (AJCC) Cancer Staging Atlas, 2nd edn. (2013)
46.
M. Xing, BRAF mutationin papillary thyroid cancer: pathogenic role, molecular bases and clinical implications. Endocr. Rev. 28, 742–762 (2007)CrossRefPubMed
47.
T.H. Kim, Y.J. Park, J.A. Lim et al., The association of the BRAFV600E mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer. Cancer 118, 1764–1773 (2012)CrossRefPubMed
48.
M. Drage, B. Howitt, J. Krane, J. Barletta et al., Fine needle aspiration diagnoses of non-infiltrative, non-invasive follicular variant of papillary thyroid carcinoma. Mod. Pathol. 28, S-134A (2015)
Metadata
Title
The evaluation of miRNAs on thyroid FNAC: the promising role of miR-375 in follicular neoplasms
Authors
Esther Diana Rossi
Tommaso Bizzarro
Maurizio Martini
Sara Capodimonti
Diletta Sarti
Tonia Cenci
Mirna Bilotta
Guido Fadda
Luigi Maria Larocca
Publication date
01-12-2016
Publisher
Springer US
Published in
Endocrine / Issue 3/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-0866-0

Other articles of this Issue 3/2016

Endocrine 3/2016 Go to the issue

Letter to the Editor

Physical exercise and dementia in patients with type 2 diabetes mellitus

Original Article

Calculation of therapeutic activity of radioiodine in Graves’ disease by means of Marinelli’s formula, using technetium (99mTc) scintigraphy

Original Article

TGR5 suppresses high glucose-induced upregulation of fibronectin and transforming growth factor-β1 in rat glomerular mesangial cells by inhibiting RhoA/ROCK signaling

Original Article

Characterisation of myocardial structure and function in adult-onset growth hormone deficiency using cardiac magnetic resonance

Erratum

Erratum to: Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia

Meta-Analysis

Antigen-based immunotherapies do not prevent progression of recent-onset autoimmune diabetes: a systematic review and meta-analysis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits